Urothelial Cancer

Jacqueline Brown, MD, discusses the nuanced potential role of immunotherapy-ADC and dual-ADC combinations in bladder cancer.

Guru P. Sonpavde, MD, discusses topline data from an exploratory analysis of CheckMate 901 in metastatic urothelial cancer.

Jacqueline Brown, MD, explains the need to determine optimal second-line bladder cancer treatments for use after enfortumab vedotin/pembrolizumab.

Jacqueline Brown, MD, discusses the current role of enfortumab vedotin plus pembrolizumab in bladder cancer and tips for early AE management.

The SunRISe-2 trial of TAR-200 plus cetrelimab in muscle-invasive bladder cancer not undergoing radical cystectomy is being discontinued.

Guru P. Sonpavde, MD, discusses initial data from a phase 1/2 trial of sacituzumab govitecan plus ipilimumab and nivolumab in metastatic urothelial cancer.

Andrea Necchi, MD, discusses treatment with TAR-200 by PD-L1 expression in BCG-unresponsive, high-risk non–muscle-invasive bladder cancer with CIS.

John K. Lee, MD, PhD, discusses safety considerations for enfortumab vedotin in the treatment of metastatic urothelial cancer.

Andrea Necchi, MD, discusses an analysis of the SunRise-4 trial evaluating TAR-200 plus cetrelimab in patients with muscle-invasive bladder cancer.

Adjuvant pembrolizumab generated a DFS benefit vs observation in patients with high-risk muscle-invasive bladder cancer after radical surgery.

BL-B01D1 displayed safety and preliminary efficacy in previously treated locally advanced or metastatic urothelial carcinoma.

Enfortumab vedotin plus pembrolizumab has been approved in Japan for first-line radically unresectable urothelial carcinoma.

Guru Sonpavde, MD, expands on findings from 2 key bladder cancer trials presented at the 2024 ESMO Congress.

Dingwei Ye, MD, PhD, discusses the initial efficacy and safety of BL-B01D1 in locally advanced or metastatic urothelial carcinoma.

Dingwei Ye, MD, PhD, discusses the safety and efficacy outcomes of a clinical trial evaluating BL-B01D1 in locally advanced or metastatic urothelial carcinoma.

Neoadjuvant TAR-200 plus cetrelimab elicited responses and was safe in muscle-invasive bladder cancer.

Terence W. Friedlander, MD, discusses adverse effects that are associated with standard enfortumab vedotin in bladder cancer.

NIAGARA was the first phase 3 study to evaluate perioperative immunotherapy plus neoadjuvant chemotherapy in cisplatin-eligible muscle-invasive bladder cancer.

Joshua Linscott, MD, PhD, discusses the use of urinary cell-free tumor DNA for MRD detection prior to repeat resection in high-risk NMIBC.

Joshua Linscott, MD, PhD, discusses the use of utDNA to predict MRD prior to repeat TURBT in patients with high-risk non-muscle invasive bladder cancer.

Terence W. Friedlander, MD, discusses updates in the frontline management of bladder cancer.

Bernard H. Bochner, MD, FACS discusses genomic complexity and heterogeneity in bladder cancer tumors.

Roger Li, MD, discusses safety data from the final analysis of the CORE-001 trial in BCG-unresponsive non–muscle-invasive bladder cancer.

Roger Li, MD, discusses the final analysis of the CORE-001 trial of cretostimogene grenadenorepvec plus pembrolizumab in BCG-unresponsive NMIBC with CIS.

The European Commission granted marketing authorization to frontline enfortumab vedotin plus pembrolizumab for unresectable/metastatic urothelial cancer.